HIF1A and COVID-19: Based on the theory developed by Zalpoor et al. the pharmacological targeting of autophagy and hypoxia-inducible factor 1 alpha (HIF-1α) may be a potential treatment for FLT3-ITD mutations with COVID-19 and risk of mortality, development of HDMs, and drug resistance [187].